Benchmarking Protein Nanoparticles for Drug Delivery and Clinical Translation
Small Methods · 2026-02 · 10 (3)
DOI: 10.1002/smtd.202501671 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Methods, online erschienen am 26.12.2025. Verfasst von Han Sol Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences (RIPS), Chosun University, Gwangju, Republic of Korea. Hauptthemen laut MEDLINE: Nanoparticles, Drug Delivery Systems, Proteins, Translational Research, Biomedical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 179 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, National Research Foundation of Korea (NRF) grants funded by the Ministry of Science and ICT, Ministry of Education and Jeollanam-do in Korea.
Abstract (Originalsprache)
Protein nanoparticles (PNs) are emerging as versatile, biocompatible platforms for drug delivery, leveraging their intrinsic biodegradability, molecular specificity, and structural tunability. They improve drug stability, prolong circulation, and enable targeted delivery, making them promising in cancer nanomedicine. This review classifies PNs into native‐ordered, native‐amorphous, and denatured categories, each distinguished by unique assembly strategies and pharmacokinetic behaviors. We discuss fabrication methods like emulsification, crosslinking, and desolvation. We also examine functionalization strategies—including PEGylation, Fc fusion, and lipidation—that enhance tumor selectivity and therapeutic efficacy. A systematic evaluation framework, encompassing physicochemical characterization, in vitro assays, and in vivo assessments, is essential for their successful translation. While clinical use is currently limited, examples like nab‐paclitaxel and virus‐like particle (VLP)‐based vaccines demonstrate their potential. We highlight persistent challenges, such as a lack of standardized evaluation methods and regulatory guidelines, and identify opportunities for innovation to accelerate the development of next‐generation protein nanomedicines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Research Institute of Pharmaceutical Sciences (RIPS), Chosun University, Gwangju, Republic of Korea.
- College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
- Department of Biomedicine, Health & Life Convergence Sciences, BK21 Four, Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam, Republic of Korea.
- College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam, Republic of Korea.
- Research Institute of Pharmaceutical Sciences and Natural Products Research Institute, Seoul National University, Seoul, Republic of Korea.
ORCID-Profile: Jae-Young Lee
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Ministry of Education
- National Research Foundation of Korea (NRF) grants funded by the Ministry of Science and ICT
- Ministry of Education and Jeollanam-do in Korea
Zitieren
APA
Lee, H. S., Choo, S., Chaudhary, M., Park, J. H., Chang, J., Byun, Y., Kim, K. T., & Lee, J. Y. (2026). Benchmarking Protein Nanoparticles for Drug Delivery and Clinical Translation. Small Methods, 10(3). https://doi.org/10.1002/smtd.202501671
Vancouver
Lee HS, Choo S, Chaudhary M, Park JH, Chang J, Byun Y, et al. Benchmarking Protein Nanoparticles for Drug Delivery and Clinical Translation. Small Methods. 2026;10(3). doi:10.1002/smtd.202501671
BibTeX
@article{Lee2026,
author = {Lee, Han Sol and Choo, Suwon and Chaudhary, Mansingh and Park, Ju Hee and Chang, Juhwan and Byun, Yejun and Kim, Ki-Taek and Lee, Jae-Young},
title = {Benchmarking Protein Nanoparticles for Drug Delivery and Clinical Translation},
journal = {Small Methods},
year = {2026},
volume = {10},
number = {3},
doi = {10.1002/smtd.202501671}
}
EUVIMED